Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9428149 | 1.00 | USP2 (0.34) | USP2ARLMNAALDH1A1CYP1A2 | |
| SCHEMBL17048382 | 1.00 | USP2 (0.34) | USP2ARLMNAALDH1A1CYP1A2 | |
| SCHEMBL4420207 | 0.89 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL10447623 | 0.83 | THRB (0.36) | — | |
| SCHEMBL3608074 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL5241702 | 0.83 | KDM4E (0.34) | KDM4E | |
| SCHEMBL1628831 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL2962445 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL59285 | 0.81 | AR (0.36) | AR | |
| SCHEMBL59286 | 0.81 | AR (0.36) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736236-B | Preparation method of hydroxyl-protected intermediate, phosphatidylethanolamine compound and preparation method thereof | 凯莱英生命科学技术(天津)有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117736236-A | Preparation method of hydroxyl-protected intermediate, phosphatidylethanolamine compound and preparation method thereof | 凯莱英生命科学技术(天津)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3110789-B1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| EP-3110789-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | ratiopharm GmbH (DE) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128488-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | TPMT, FH, FAH | USP2 1561/4885AR 3999/4885LMNA 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.